NCT05346653 is a Phase 4 clinical trial of SGLT2i in Acute Decompensated Heart Failure, sponsored by University of Chicago.

Who is sponsoring NCT05346653?

NCT05346653 is sponsored by University of Chicago.

What drugs are being tested in NCT05346653?

Interventions in NCT05346653: SGLT2i, No SGLT2i.

What condition does NCT05346653 study?

NCT05346653 studies Acute Decompensated Heart Failure.

Is NCT05346653 still recruiting?

NCT05346653 is currently terminated. Last updated 4 September 2024.

Are results published for NCT05346653?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-04 · How we verify

NCT05346653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

Terminated Phase 4 Results posted Last updated 4 September 2024

What this trial tests

Phase 4 trial testing SGLT2i in Acute Decompensated Heart Failure in 1 participant. Terminated before completion.

Timeline

22 May 2023

Primary endpoint
23 May 2023

23 May 2023

Quick facts

Lead sponsor	University of Chicago
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	22 May 2023
Primary completion	23 May 2023
Estimated completion	23 May 2023
Sites	1 location across United States

Drugs / interventions tested

SGLT2i — full drug profile →
No SGLT2i

Conditions studied

Acute Decompensated Heart Failure — all drugs for Acute Decompensated Heart Failure →

Sponsor

University of Chicago

Who can join

18 and older, any sex, with Acute Decompensated Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
Ul Amin N, Sabir F, Amin T, Sarfraz Z, et al · · 2022 · cited 19× · PMID 36553880 · DOI 10.3390/healthcare10122356
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives.
Popa IP, Haba MȘC, Mărănducă MA, Tănase DM, et al · · 2022 · cited 11× · PMID 36145711 · DOI 10.3390/pharmaceutics14091964

Verify or expand the search:

Other trials of SGLT2i

Trials testing the same drug.

NCT06147271 — Impact of SGLT2 Inhibitors in Heart Transplant Recipients · Phase 2 · enrolling by invitation
NCT05278962 — HF Patients With LVADs Being Treated With SGLT2i · Phase 4 · completed
NCT05073692 — Comparison of Type 2 Diabetes Pharmacotherapy Regimens · completed
NCT05535322 — Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inerti · completed

Other recruiting trials for Acute Decompensated Heart Failure

Currently open trials in the same condition.

NCT07372040 — Add-on Diuretics in Acute Decompensated Heart Failure · Phase 2 · recruiting
NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
NCT06556810 — IC14 for Treatment of Acute Decompensated Heart Failure · Phase 1, PHASE2 · active not recruiting
NCT06714409 — Venous Ultrasound Guided Organ Decongestion in Patients Hospitalized with Acute Decompensated Heart Failure · NA · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05346653 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 4 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05346653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing